A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

Inclusion Criteria:

1. Voluntary participation and written informed consent;

2. 18-75 years older, no gender limitation;

3. Eastern Cooperative Oncology Group (ECOG) score: 0-1;

4. With a life expectancy ≥ 3 months;

5. Pathologically diagnosed advanced solid tumor;

6. Be able to provide fresh or archived tumour tissue;

7. At least one measurable lesion according to RECIST v1.1;

8. Adequate bone marrow reserve and organ function;

9. Contraception is required during clinical trials, and pregnancy tests must benegative for women of childbearing age within 7 days before the first dose.

Exclusion Criteria:

1. Meningeal metastasis history or clinical symptoms of central nervous systemmetastasis;

2. Previous or co-existing malignancies;

3. Spinal cord compression that was not treated radically by surgery and/orradiotherapy was excluded;

4. Uncontrollable tumor-related pain;

5. Previously received antiboy-coupled drug therapy with topoisomerase I inhibitortoxin; Previously received EGFR/c-Met double antibody;

6. Received systemic antitumor therapy before the first dose;

7. Have undergone major surgery other than diagnosis or biopsy within 28 days prior toinitial dosing; Minor traumatic surgery within 7 days prior to first dosing;

8. For the first time, a study was conducted to treat patients with radiation therapyexceeding the prescribed dose before study treatment;

9. Received Other investigational drugs treatments 4 weeks prior to the initiation ofthe study treatment;

10. Unresolved CTCAE 5.0>grade 2 toxicities from previous anticancer therapy;

11. A history of interstitial pneumonia/non-infectious pneumonia;

12. Accompanied by uncontrolled pleural effusion and pericardial effusion; Moderate orsevere ascites with clinical symptoms;

13. Study the presence of intestinal obstruction or the presence of signs or symptoms ofintestinal obstruction 6 months before first dosing;

14. With poorly controlled or severe cardiovascular disease;

15. Active hepatitis B, hepatitis C;

16. Patients with a history of immunodeficiency;

17. Severe infection 30 days before the first dose.